A randomised controlled trial to evaluate the effect of inhaled glycopyrrolate in improving the fibreoptic intubating conditions under general anaesthesia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- To evaluate and compare the degree of airway secretion with or without use of inhaled glycopyrrolate prior to fibreoptic intubation
Study Overview
Brief Summary
In this study, inhaled glycopyrrolate is used as a premedication inorder to reduce the airway secretions to improve the fibreoptic visual field during nasotracheal intubation.
According to DAS guidelines for awake tracheal intubation,use of systemic antisialogogue is not mandatory, however its also stated that fibrescopy view may be improved with antisialogogue.
Inhaled glycopyrrolate ,currently approved for management of COPD has not been evaluated for its anti secretory effect.Hence usage of inhaled glycopyrrolate is expected to have less systemic side effects and thus can be a better alternative to systemic antisialogogue.
Study Design
- Study Type
- Interventional
- Allocation
- Permuted block randomization, fixed
- Masking
- Participant and Investigator Blinded
Eligibility Criteria
- Ages
- 18.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •ASA physical status 1 and 2 of either sex undergoing elective surgery Age of 18 to 65 years Anticipated difficult airway in which fibreoptic intubation is planned under general anaesthesia.
Exclusion Criteria
- •Patients in which other modalities of intubation is planned Airway obstruction.
Outcomes
Primary Outcomes
To evaluate and compare the degree of airway secretion with or without use of inhaled glycopyrrolate prior to fibreoptic intubation
Time Frame: Intraoperative at the time of fibreoptic intubation
Secondary Outcomes
- Time to reach carina(The change in heart rate and blood pressure 20 min after nebulization)